Opioid-Axis Component
Alcohol consumption stimulates the release of endogenous opioids (such as beta-endorphins) in the brain's reward centers. These endogenous opioids bind to mu-opioid receptors, which inhibits GABAergic interneurons and subsequently triggers a surge in dopamine release within the nucleus accumbens. This dopaminergic cascade is the neurochemical engine of alcohol's reinforcing "high" and the reward learning that drives compulsive drinking behavior.
Naltrexone acts as a competitive antagonist at these mu-opioid receptors, effectively blocking the reward signaling pathway at its origin. Within Trivalent's IP portfolio, naltrexone serves as the crucial opioid-axis arm of a dual-pathway, bimodal therapeutic approach to alcohol use disorder (AUD).
The same blockade acts directly on exogenous opioids, which is why naltrexone is also an approved relapse-prevention therapy for opioid use disorder (OUD) in patients who have completed medically supervised withdrawal. Trivalent's filed method claims therefore reach OUD as an adjacent, investigational indication: the incretin arm is hypothesised to address the craving and cue-driven relapse that opioid blockade alone leaves untouched. That approval belongs to naltrexone as a single agent, not to the combination — no clinical data exist for the combination in any indication.
By competitively binding to mu-opioid receptors with high affinity, naltrexone prevents endogenous opioids from engaging the receptors. Consequently, even when alcohol is consumed, the reward response is heavily blunted. Rather than causing physical aversion, naltrexone alters the psychological response: it reduces the "priming" effect (where one drink triggers an intense craving for another) and assists patients in maintaining abstinence by breaking the reinforcement loop.
Naltrexone is orally bioavailable and metabolized in the liver to its active metabolite, 6-beta-naltrexol, which also contributes to mu-opioid blockade. This pharmacological profile makes it highly suitable for daily oral administration or long-acting injectable formulations.
Approved by the FDA for opioid dependence in 1984 and for alcohol dependence in 1994, naltrexone is one of the few established pharmacotherapies in either disorder. In AUD, extensive clinical trial data and meta-analyses have demonstrated its efficacy in:
In OUD, naltrexone prevents relapse by blocking the effects of opioids outright, but it can only be started after full detoxification and is limited in practice by discontinuation and by cravings that persist despite receptor blockade.
However, as a monotherapy, naltrexone's efficacy in either indication is often limited by compliance issues, individual genetic variations in the mu-opioid receptor gene (OPRM1), and the fact that it does not address the metabolic-reward pathways or the anticipatory salience of food, alcohol, or drug cues. By pairing it with a triple incretin agonist (retatrutide), Trivalent's methods aim to address these limitations, targeting the addiction loop from both ends.
When naltrexone's post-consumption reward blockade is combined with retatrutide's pre-consumption metabolic-reward modulation, the result is a true pharmacological synergy:
Trivalent's portfolio covers combination methods pairing retatrutide with naltrexone across multiple claim families in alcohol use disorder, with opioid use disorder as an adjacent, investigational indication. Partner with us to develop the next generation of addiction treatments.
Licensing Inquiries